Approval · Notice of Compliance 7089 · 2005

CRIXIVAN: Notice of Compliance 7089

Issued June 8, 2005

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 7089
Date: June 8, 2005
Company: Merck Frosst Canada Ltd., Merck Frosst Canada Ltée
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Manufacturer name change
Therapeutic class: Hiv protease inhibitor

Products in this notice

Brand	DIN	Status today
CRIXIVAN	02229153	—
CRIXIVAN	02229161	Cancelled Post Market
CRIXIVAN	02229188	Cancelled Pre Market
CRIXIVAN	02229196	Cancelled Post Market

Medicinal ingredients

INDINAVIR SULFATE 100 MG per CAP
INDINAVIR SULFATE 200 MG per CAP
INDINAVIR SULFATE 300 MG per CAP
INDINAVIR SULFATE 400 MG per CAP